BCL2 and Miyoshi myopathy: Over the past two decades, the incidence of MM has increased globally by 126% whereas the age-standardized mortality rate has been steadily falling [1] due to the utilization of novel agents [e.g., immunomodulatory drugs (IMiDs), the proteasome inhibitors (PIs), monoclonal antibodies, BCL2 inhibitor, etc.] in the treatment of MM [2–4].